Sirtex Medical Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
129,363.00
176,088.00
232,492.00
234,282.00
218,735.00
Cost of Goods Sold (COGS) incl. D&A
20,356.00
27,700.00
35,287.00
38,395.00
37,570.00
Gross Income
109,007.00
148,388.00
197,205.00
195,887.00
181,165.00
SG&A Expense
79,449.00
99,633.00
128,467.00
146,400.00
120,815.00
EBIT
29,181.00
48,755.00
68,738.00
-
59,942.00
Unusual Expense
-
-
1,389.00
91,178.00
-
Non Operating Income/Expense
53.00
2,124.00
420.00
1,282.00
2,673.00
Pretax Income
31,110.00
52,768.00
69,998.00
40,954.00
59,271.00
Income Tax
7,242.00
12,423.00
16,416.00
14,697.00
17,802.00
Consolidated Net Income
23,868.00
40,345.00
53,582.00
26,257.00
41,469.00
Net Income
23,868.00
40,345.00
53,582.00
26,257.00
41,469.00
Net Income After Extraordinaries
23,868.00
40,345.00
53,582.00
26,257.00
41,469.00
Net Income Available to Common
23,868.00
40,345.00
53,582.00
26,257.00
41,469.00
EPS (Basic)
0.43
0.71
0.94
0.45
0.74
Basic Shares Outstanding
56,097.80
56,511.10
57,197.60
57,668.70
56,125.20
EPS (Diluted)
0.41
0.70
0.92
0.46
0.73
Diluted Shares Outstanding
57,763.20
57,863.70
58,139.60
57,668.70
56,723.50
EBITDA
30,773.00
51,134.00
75,305.00
55,777.00
63,318.00
Other Operating Expense
377.00
-
-
626.00
408.00
Non-Operating Interest Income
1,876.00
1,889.00
2,229.00
2,645.00
2,002.00

About Sirtex Medical

View Profile
Address
101 Miller Street
North Sydney New South Wales (NSW) 2060
Australia
Employees -
Website http://www.sirtex.com
Updated 09/14/2018
Sirtex Medical Ltd. engages in the research, commercial development, manufacture, and distribution of liver cancer treatments. It offers targeted radiation therapy known as SIR-Spheres Y-90 resin microspheres. Its clinical programs include SIRFLOX, FOXFIRE/FOXFIRE Global, SARAH, SIRveNIB, and SORAMIC.